Acrobiosystems Co

Acrobiosystems Co Revenue

The The revenue of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 838.12 M CNY. In the previous year, The revenue was 645.02 M CNY — a change of 29.94% (higher).

Revenue

838.12 MCNY

YoY

29.94%

Last updated:

In 2025, Acrobiosystems Co's sales reached 838.12 M CNY, a 29.94% difference from the 645.02 M CNY sales recorded in the previous year.

Revenue has compounded at 42.6% per year over the past 7 years to 838.12 M CNY.

The Acrobiosystems Co Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2020
246.32 M CNY
Jan 1, 2021
384.99 M CNY
Jan 1, 2022
474.43 M CNY
Jan 1, 2023
543.65 M CNY
Jan 1, 2024
645.02 M CNY
Jan 1, 2025
838.12 M CNY
Jan 1, 2026 (e)
1.08 B CNY
Jan 1, 2027 (e)
1.32 B CNY
The Acrobiosystems Co Revenue history
YEARRevenueYoY
est1.32 BCNY+23.15%
est1.08 BCNY+28.26%
838.12 MCNY+29.94%
645.02 MCNY+18.65%
543.65 MCNY+14.59%
474.43 MCNY+23.23%
384.99 MCNY+56.30%
246.32 MCNY+138.47%
103.29 MCNY+47.90%
69.84 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Revenue

Acrobiosystems Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
246.32 M CNY
139.97 M CNY
115.88 M CNY
Jan 1, 2021
384.99 M CNY
196.31 M CNY
174.21 M CNY
Jan 1, 2022
474.43 M CNY
165.63 M CNY
203.73 M CNY
Jan 1, 2023
543.65 M CNY
132.42 M CNY
153.59 M CNY
Jan 1, 2024
645.02 M CNY
109.32 M CNY
123.83 M CNY
Jan 1, 2025
838.12 M CNY
196.96 M CNY
165.57 M CNY
Jan 1, 2026 (e)
1.08 B CNY
220.21 M CNY
227.36 M CNY
Jan 1, 2027 (e)
1.32 B CNY
301.15 M CNY
329.34 M CNY

Acrobiosystems Co Margins

Acrobiosystems Co stock margins

The Acrobiosystems Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acrobiosystems Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acrobiosystems Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
91.91 %
56.83 %
47.05 %
Jan 1, 2021
92.57 %
50.99 %
45.25 %
Jan 1, 2022
92.51 %
34.91 %
42.94 %
Jan 1, 2023
91.26 %
24.36 %
28.25 %
Jan 1, 2024
90.93 %
16.95 %
19.20 %
Jan 1, 2025
91.16 %
23.50 %
19.75 %
Jan 1, 2026 (e)
91.16 %
20.48 %
21.15 %
Jan 1, 2027 (e)
91.16 %
22.75 %
24.88 %

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Acrobiosystems Co's Sales Figures

The sales figures of Acrobiosystems Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Acrobiosystems Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Acrobiosystems Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Acrobiosystems Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Acrobiosystems Co stock

The revenue of Acrobiosystems Co is 838.12 M CNY in 2025.

The revenue of Acrobiosystems Co changed from 645.02 M CNY to 838.12 M CNY, representing a 29.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Acrobiosystems Co historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co